MedTrace Logo

Benefit of DAA Therapy in HCV Monoinfected and HIV-HCV Coinfected Patients With Mixed Cryoglobulinemia

NCT03342261 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 47

Last updated 2017-11-14

No results posted yet for this study

Summary

Mixed cryoglobulinemia (MC) is common in patients with chronic hepatitis C virus (HCV) infection. Direct-acting antiviral (DAA) regimens are today very effective with sustained virological response rates (SVR12) above 90%. The objective of this study was to investigate the impact of DAA therapy on cryoglobulin clearance in patients with HCV-associated MC.

Conditions

  • Hepatitis C, Chronic
  • Mixed Cryoglobulinemia

Interventions

DRUG

DAA treatment

Patients were treated with direct-acting antiviral (DAA) treatment for 12 or 24 weeks

Sponsors & Collaborators

  • Hospices Civils de Lyon

    lead OTHER

Principal Investigators

  • Fabien Zoulim, MD, PhD · Hospices Civils de Lyon

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2017-11-01
Completion
2017-11-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03342261 on ClinicalTrials.gov